收费全文 | 15658篇 |
免费 | 1057篇 |
国内免费 | 109篇 |
耳鼻咽喉 | 133篇 |
儿科学 | 245篇 |
妇产科学 | 296篇 |
基础医学 | 2634篇 |
口腔科学 | 323篇 |
临床医学 | 1358篇 |
内科学 | 3105篇 |
皮肤病学 | 268篇 |
神经病学 | 1554篇 |
特种医学 | 645篇 |
外国民族医学 | 1篇 |
外科学 | 2196篇 |
综合类 | 150篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 1272篇 |
眼科学 | 419篇 |
药学 | 1111篇 |
中国医学 | 32篇 |
肿瘤学 | 1076篇 |
2023年 | 80篇 |
2022年 | 240篇 |
2021年 | 532篇 |
2020年 | 267篇 |
2019年 | 303篇 |
2018年 | 420篇 |
2017年 | 286篇 |
2016年 | 335篇 |
2015年 | 425篇 |
2014年 | 547篇 |
2013年 | 691篇 |
2012年 | 1028篇 |
2011年 | 1150篇 |
2010年 | 612篇 |
2009年 | 555篇 |
2008年 | 918篇 |
2007年 | 915篇 |
2006年 | 820篇 |
2005年 | 891篇 |
2004年 | 802篇 |
2003年 | 724篇 |
2002年 | 717篇 |
2001年 | 263篇 |
2000年 | 253篇 |
1999年 | 230篇 |
1998年 | 153篇 |
1997年 | 140篇 |
1996年 | 106篇 |
1995年 | 105篇 |
1994年 | 91篇 |
1993年 | 72篇 |
1992年 | 107篇 |
1991年 | 107篇 |
1990年 | 130篇 |
1989年 | 113篇 |
1988年 | 95篇 |
1987年 | 86篇 |
1986年 | 92篇 |
1985年 | 100篇 |
1984年 | 81篇 |
1983年 | 91篇 |
1982年 | 72篇 |
1981年 | 71篇 |
1980年 | 75篇 |
1979年 | 101篇 |
1978年 | 66篇 |
1977年 | 64篇 |
1976年 | 56篇 |
1975年 | 55篇 |
1974年 | 61篇 |
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献Methods: An experimental bronchopneumonia was induced in anesthetized piglets by inoculating lower lobes with a suspension of 106 cfu/ml Escherichia coli. After 24 h of mechanical ventilation, 7 animals received two intravenous injections of 15 mg/kg amikacin, and 11 animals received two nebulizations of 40 mg/kg amikacin at 24-h intervals. One hour following the second administration, animals were killed, and multiple lung specimens were sampled for assessing amikacin pulmonary concentrations and quantifying lung aeration on histologic sections.
Results: Thirty-eight percent of the nebulized amikacin (15 mg/kg) reached the tracheobronchial tree. Amikacin pulmonary concentrations were always higher after nebulization than after intravenous administration, decreased with the extension of parenchymal infection, and were significantly influenced by lung aeration: 197 +/- 165 versus 6 +/- 5 [mu]g/g in lung segments with focal bronchopneumonia (P = 0.03), 40 +/- 62 versus 5 +/- 3 [mu]g/g in lung segments with confluent bronchopneumonia (P = 0.001), 18 +/- 7 versus 7 +/- 4 [mu]g/g in lung segments with lung aeration of 30% or less, and 65 +/- 9 versus 2 +/- 3 [mu]g/g in lung segments with lung aeration of 50% or more. 相似文献